

**Predicting treatment effects of a new-to-market drug in clinical practice based on phase III  
randomized trial results.**

**Author Name(s) and Affiliation:**

HoJin Shin, BPharm, PhD<sup>1</sup>; Shirley V. Wang PhD<sup>1</sup>; Dae Hyun Kim, MD, MPH, ScD<sup>1,2</sup>; Ethan Alt,  
PhD<sup>1,\*</sup>; Mufaddal Mahesri, MD, MPH<sup>1</sup>; Lily G. Bessette, MS<sup>1</sup>; Sebastian Schneeweiss, MD, ScD<sup>1</sup>;

Mehdi Najafzadeh, PhD<sup>1,\*\*</sup>